Ankylosing Spondylitis — Deal Benchmarks & Valuation
Market Analysis
Ankylosing Spondylitis is one of the most actively transacted indications in immunology licensing. Phase 2 deals for ankylosing spondylitis carry a median total deal value of $2.7B, with upfront payments ranging from $276M to $754M. The recommended deal structure allocates approximately 19% to upfront payments and 81% to milestones.
Milestone structures for ankylosing spondylitis deals allocate $439M to development milestones, $768M to regulatory milestones, and $988M to commercial milestones. Royalty rates range from 13.6% to 22.6% at the base tier, with tiered escalation reaching 17.6%-26.6% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for ankylosing spondylitis licensing?
What royalty rates are standard for ankylosing spondylitis deals?
How are ankylosing spondylitis deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.